These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33512408)

  • 21. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
    Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
    Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.
    Wang J; Lau KY; Jung J; Ravindran P; Barrat FJ
    Eur J Immunol; 2014 Apr; 44(4):1130-6. PubMed ID: 24375473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-trans retinoic acid increases NF-κB activity in PMA-stimulated THP-1 cells upon unmethylated CpG challenge by enhancing cell surface TLR9 expression.
    Trinh TA; Hoang TX; Kim JY
    Mol Cell Biochem; 2020 Oct; 473(1-2):167-177. PubMed ID: 32638255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
    Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
    Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
    Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
    Christensen DJ; Chen Y; Oddo J; Matta KM; Neil J; Davis ED; Volkheimer AD; Lanasa MC; Friedman DR; Goodman BK; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Vitek MP; Weinberg JB
    Blood; 2011 Oct; 118(15):4150-8. PubMed ID: 21844565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
    Bomben R; Gobessi S; Dal Bo M; Volinia S; Marconi D; Tissino E; Benedetti D; Zucchetto A; Rossi D; Gaidano G; Del Poeta G; Laurenti L; Efremov DG; Gattei V
    Leukemia; 2012 Jul; 26(7):1584-93. PubMed ID: 22343732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes.
    Chatzouli M; Ntoufa S; Papakonstantinou N; Chartomatsidou E; Anagnostopoulos A; Kollia P; Ghia P; Muzio M; Stamatopoulos K; Belessi C
    J Immunol; 2014 May; 192(10):4518-24. PubMed ID: 24719462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of
    Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
    Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.
    Lee KG; Xu S; Wong ET; Tergaonkar V; Lam KP
    J Biol Chem; 2008 Apr; 283(17):11189-98. PubMed ID: 18276597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
    Herman SE; Sun X; McAuley EM; Hsieh MM; Pittaluga S; Raffeld M; Liu D; Keyvanfar K; Chapman CM; Chen J; Buggy JJ; Aue G; Tisdale JF; Pérez-Galán P; Wiestner A
    Leukemia; 2013 Dec; 27(12):2311-21. PubMed ID: 23619564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells.
    Grandjenette C; Kennel A; Faure GC; Béné MC; Feugier P
    Haematologica; 2007 Sep; 92(9):1279-81. PubMed ID: 17768129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
    J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.
    Riches JC; O'Donovan CJ; Kingdon SJ; McClanahan F; Clear AJ; Neuberg DS; Werner L; Croce CM; Ramsay AG; Rassenti LZ; Kipps TJ; Gribben JG
    Blood; 2014 Jun; 123(26):4101-10. PubMed ID: 24829201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.